IMC Chicago
CLPT icon

IMC Chicago’s ClearPoint Neuro CLPT Stock Holding History

IMC Chicago’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$473K Sell
26,494
-21,049
-44% -$263K ﹤0.01% 4713
2026
Q1 		$433K Buy
+47,543
New +$600K ﹤0.01% 4202

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PC
Pier Capital Stamford, Connecticut $755M AUM 94.38% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $214M AUM 47.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CCM
Conway Capital Management Burbank, California $225M AUM 19.09% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

IMC Chicago's CLPT Position: Q2 2026 in Review

IMC Chicago reduced its ClearPoint Neuro (CLPT) stake by 44% in Q2 2026, selling an estimated $263K and leaving 26,494 shares worth $473K. The position accounts for ﹤0.01% of the portfolio, ranked #4713.

IMC Chicago first reported a position in CLPT in Q1 2026 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • IMC Chicago held 26,494 shares of ClearPoint Neuro worth $473K as of Q2 2026.
  • IMC Chicago sold 21,049 ClearPoint Neuro shares in Q2 2026, an estimated $263K.
  • ClearPoint Neuro made up ﹤0.01% of IMC Chicago's portfolio in Q2 2026, its #4713 holding.
  • IMC Chicago first reported a position in ClearPoint Neuro in Q1 2026 and has held it in 2 quarters since.
  • 49 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.